News & Updates

Refractory Crohn’s disease responds well to risankizumab
Refractory Crohn’s disease responds well to risankizumab
09 Jan 2023

In the treatment of patients with luminal Crohn’s disease and multiple prior drug failures, risankizumab induces clinical response in about three out of four patients and steroid-free clinical remission in about half, according to a study.

Refractory Crohn’s disease responds well to risankizumab
09 Jan 2023
Oseltamivir as good as peramivir in influenza B but yields better outcomes in influenza A
Oseltamivir as good as peramivir in influenza B but yields better outcomes in influenza A
08 Jan 2023
Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
07 Jan 2023

Adagrasib appears to have some effect against metastatic, KRAS G12C-mutated colorectal cancer when used in treatment-experienced patients either as oral monotherapy or in combination with cetuximab, according to the results of a phase I-II, open-label study.

Adagrasib shows antitumour activity in KRAS G12C-mutant colorectal cancer
07 Jan 2023
Cardiovascular, mortality outcomes in hypertension similar between two thiazide diuretics
Cardiovascular, mortality outcomes in hypertension similar between two thiazide diuretics
06 Jan 2023

The use of chlorthalidone in the treatment of patients with hypertension does not appear to provide better protection against major cardiovascular outcome events or noncancer-related deaths when compared with hydrochlorothiazide, according to a study.

Cardiovascular, mortality outcomes in hypertension similar between two thiazide diuretics
06 Jan 2023
Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
06 Jan 2023

The age of patients with advanced breast cancer appears to have no influence on the rate of palbociclib dose reductions or discontinuations secondary to neutropaenia, a study has shown.

Age does not affect palbociclib dose reduction, discontinuation in breast cancer patients
06 Jan 2023